Shah K, Price A B, Talbot I C, Bardhan K D, Fenn C G, Bjarnason I
Department of Histopathology, Northwick Park Hospital, London.
Gut. 1995 Aug;37(2):195-8. doi: 10.1136/gut.37.2.195.
Prostaglandins are widely used in the prevention and healing of non-steroidal anti-inflammatory drug (NSAID) induced gastric and duodenal ulcers, but their longterm effect on the human gastric mucosa is unknown. This study assessed the effect of coadministration of prostaglandins with NSAIDs on the histology of the gastroduodenal mucosa. Histological appearances (using the Sydney system) of gastric biopsy specimens from 180 patients receiving longterm NSAID treatment of whom 90 had been receiving misoprostol (400-800 micrograms/day) for one to two years were studied. Both groups of patients were comparable with regard to clinical and demographic details. There was no significant difference (p > 0.1) in the prevalence of chronic gastritis (total, corpus or antrum only) between patients receiving (36 of 90 (40%)) or not receiving misoprostol (35 of 90 (39%)). Chronic gastritis was equally associated with the presence of Helicobacter pylori, 86% and 73% (p > 0.1), respectively, in the two groups. Significantly fewer patients receiving misoprostol had reactive gastritis than those receiving only NSAIDs (8 (9%) versus 27 (30%), p < 0.01). Reactive gastritis was not associated with H pylori. Thirty nine (43%) of the misoprostol treated patients had normal histology compared with 16 (18%) receiving only NSAIDs (p < 0.01). These results show two different patterns of gastric damage in patients receiving NSAIDs, namely chronic and reactive gastritis. Misoprostol treatment was associated with a significantly reduced prevalence of reactive gastritis and it is suggested that this, along with its antisecretory action, may explain the reduced prevalence of gastroduodenal lesions when coadministered with NSAIDs.
前列腺素广泛用于预防和治疗非甾体抗炎药(NSAID)引起的胃和十二指肠溃疡,但其对人胃黏膜的长期影响尚不清楚。本研究评估了前列腺素与NSAIDs联合使用对胃十二指肠黏膜组织学的影响。对180例接受长期NSAID治疗的患者的胃活检标本进行组织学检查(采用悉尼系统),其中90例患者接受米索前列醇(400 - 800微克/天)治疗一至两年。两组患者在临床和人口统计学细节方面具有可比性。接受米索前列醇治疗的患者(90例中的36例(40%))和未接受米索前列醇治疗的患者(90例中的35例(39%))之间,慢性胃炎(仅累及全胃、胃体或胃窦)的患病率无显著差异(p>0.1)。两组中,慢性胃炎与幽门螺杆菌感染的相关性相同,分别为86%和73%(p>0.1)。接受米索前列醇治疗的患者中,反应性胃炎的发生率显著低于仅接受NSAIDs治疗的患者(8例(9%)对27例(30%),p<0.01)。反应性胃炎与幽门螺杆菌无关。接受米索前列醇治疗的患者中有39例(43%)组织学正常,而仅接受NSAIDs治疗的患者中这一比例为16例(18%)(p<0.01)。这些结果显示,接受NSAIDs治疗的患者存在两种不同类型的胃损伤,即慢性胃炎和反应性胃炎。米索前列醇治疗与反应性胃炎的发生率显著降低相关,提示这一点连同其抗分泌作用,可能解释了与NSAIDs联合使用时胃十二指肠病变发生率降低的原因。